Loading...
Loading...
Horizon Pharma, Inc.
HZNP today announced that SkyePharma has received a Notice
of Allowance from the United States Patent and Trademark Office for
U.S. Patent Application 2012/0177734 entitled "Delayed Release Tablet
with Defined Core Geometry" that covers the U.S. approved product
RAYOS(R).
This Notice of Allowance concludes the substantive examination of the
patent application and will result in the issuance of a U.S. patent
after administrative processes are completed. The patent scheduled to
issue from this application will expire in 2024 for the U.S. patent.
After issuance, Horizon plans to list the U.S. patent in the FDA's
Approved Drug Products with Therapeutic Equivalence Evaluations, or
Orange Book.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in